Name

Dopavision

Legal name

Dopavision GmbH

Website

https://dopavision.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Dopavision is a Berlin-based clinical-stage digital therapeutics company developing MyopiaX®, a smartphone- and VR-based digital therapeutic that uses selective ocular light stimulation to slow myopia progression in children and adolescents.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Pediatric Myopia

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Contact Lens Specialty & Myopia Control (HLAKAKAK)

akta.pro secondary industries

Vision Therapy & Orthoptics (HLAKAKAM), Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)

Keywords

• Digital therapeutics
• Myopia control
• Ophthalmic medical devices
• Light-based therapy
• Pediatric eye care

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Digital Therapeutic Product (MyopiaX): The company is developing a prescription digital therapeutic for childhood myopia control. Revenue model not yet publicly disclosed as product is still in clinical trial stage.

Distribution channels2 records

Marketing channels3 records

Core offering

Dopavision develops MyopiaX®, a smartphone-based prescription digital therapeutic that delivers patented selective ocular light stimulation through a VR headset and Bluetooth controller to slow the progression of myopia in children aged 6–14. The product is administered as twice-daily gamified VR sessions targeting melanopsin-mediated dopamine pathways in the retina, and is currently being evaluated as a regulated medical device in the MyopiaX-1 clinical trial (NCT04967287) across Europe.

Product overview

Dopavision is a digital therapeutics company offering MyopiaX®, a single core product consisting of a smartphone application that delivers selective ocular light stimulation through consumer electronics (VR headset and Bluetooth controller). MyopiaX® is designed as an interactive, game-based therapeutic where children use the app twice daily to receive light-based treatment targeting the dopamine pathway to slow myopia progression. The product is under clinical investigation (MyopiaX-1 trial NCT04967287) and is being developed as a medical device meeting EN 62304 and ISO 14971 standards.

Differentiator

Problem solved

Functional benefit

Brands

• MyopiaX®: Lead product - a smartphone application that administers selective ocular light stimulation via VR headset to slow myopia progression in children. It delivers therapeutic intervention while children play games or use educational digital content.

Products and services

• MyopiaX®

Quantifiable outcome

• MyopiaX treatment group showed 0.14 mm axial length change and -0.19 D spherical equivalent refraction at 6 months in MyopiaX-1 trial (n=50)

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Flying HealthminorStrategic or Co-development PartnerDigital health ecosystem partner providing access to healthcare system and industry network. Flying Health co-founders Markus Müschenich and Christian Lautner were founding investors.
• Centre for Eye Research Ireland (Technological University Dublin)coreStrategic or Co-development PartnerCoordinating center for MyopiaX-1 clinical trial led by Prof. Ian Flitcroft and Prof. James Loughman. Provides clinical research expertise in ophthalmology.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Akili Interactive: Pure-play prescription digital therapeutics company (FDA-cleared EndeavorRx for pediatric ADHD). Directly comparable in regulatory model (prescription digital therapeutic with gamified UI on consumer devices) and in commercial challenges of provider reimbursement, distribution and adherence.

Others

• Pear Therapeutics: Pioneer of FDA-authorized prescription digital therapeutics (reSET, reSET-O) for substance use disorder and opioid use disorder. Historically the closest comparable pure-play digital therapeutics company; its 2023 bankruptcy and asset sale illustrate the commercial and reimbursement risks inherent to the category Dopavision is entering.

Broad incumbents

• Bausch + Lomb: Large ophthalmology and vision-care incumbent with a myopia management portfolio (contact lenses, orthokeratology lens designs, and partnerships). Competes for the same optometry/ophthalmology channel and pediatric myopia patient population.
• Hoya Vision Care (MiYOSMART): Spectacle lens giant whose MiYOSMART lenses incorporate patented D.I.M.S. (Defocus Incorporated Multiple Segments) technology for myopia control. Alternative non-invasive pediatric myopia intervention competing for the same optometry/ophthalmology prescribing channel.
• CooperVision (MiSight): Global contact lens manufacturer whose MiSight 1 day is the first FDA-approved soft contact lens for myopia control in children. Competes for the same prescribing eye-care professional and the same pediatric myopia patient, but via an optical/pharmaceutical-adjacent device rather than a digital therapeutic.
• EssilorLuxottica (Stellest): Global lens incumbent whose Stellest spectacle lenses (Highly Aspherical Lenslets) target myopia progression in children and are sold through ophthalmology and optometry practices. Competes for the same patient and prescriber channel with a non-digital modality.
• SightGlass Vision: Joint venture (now under CooperVision) developing Diffusion Optics Technology (DOT) spectacle lenses for slowing myopia progression. Comparable in targeting pediatric myopia control through an eye-care professional prescription channel.
• Novartis Pharmaceuticals: Global ophthalmology incumbent (Lucentis, Beovu, Xiidra) and a Dopavision Series A investor. Highly relevant as a comparable end-stage commercializer of an ophthalmology product franchise and as the most likely strategic acquirer/partner given existing investor relationships and former-employees on the team.

Direct peers

• Luminopia: Digital therapeutic company that received FDA De Novo authorization for a VR-based pediatric ophthalmology treatment (amblyopia). Directly comparable in regulatory pathway (Rx digital therapeutic, novel pediatric device, novel modality) and in integrating VR hardware with a clinical-grade software therapeutic in ophthalmology.
• Eyerising International: Australian medtech company marketing a CE-marked repeated low-level red light (RLRL) therapy device for childhood myopia control. Direct competitor to MyopiaX — same disease (pediatric myopia), same intervention concept (light-based), different light modality and hardware form factor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dopavision